Skip directly to content

What to Expect With SOMAVERT

What To Expect With SOMAVERT
 

In one study, 82% of patients treated with 20 milligrams (mg) daily of SOMAVERT achieved normal IGF-I levels at 12 weeks.*

In this same study, the overall measured signs and symptoms of acromegaly (swelling, joint pain, headache, sweating, and weakness) improved in patients who took SOMAVERT compared with those who took a placebo.

The majority of IGF-I normalization occurred within the first 2 weeks for patients taking SOMAVERT.
In the same 12-week study, of the 57 patients who reached a normal IGF-I level and had at least one sign or symptom of acromegaly at that time, 91% reported improvement in these signs and symptoms at the time of normalization or thereafter.
*These data are from a clinical trial that involved 112 patients with acromegaly. 32 patients received a placebo. 80 were treated with SOMAVERT at one of 3 doses. Results for patients achieving normal IGF-I levels for their age were 10% of patients taking a placebo; 39% of those on 10 mg per day of SOMAVERT; 75% of those on 15 mg per day of SOMAVERT; and 82% of those on 20 mg per day of SOMAVERT.
References: 1. SOMAVERT [prescribing information]. New York, NY: Pfizer Inc; 2014. 2. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342(16):1171-1177.

In a long-term extension to the original clinical trial, the majority of patients treated with SOMAVERT reached normal IGF-I levels for their age.

In fact, at the end of 43 weeks, 93% of patients had a normal IGF-I level at some point during the study.

These data come from the extensions to the original clinical study of 109 patients (including 6 new patients).